Journal of Surgery Concepts & Practice ›› 2022, Vol. 27 ›› Issue (02): 139-144.doi: 10.16139/j.1007-9610.2022.02.011
• Experts forum • Previous Articles Next Articles
REN Jiajun, CHEN Yongjun(
)
Received:2022-04-10
Online:2022-05-25
Published:2022-06-16
Contact:
CHEN Yongjun
E-mail:cyj10651@rjh.com.cn
CLC Number:
REN Jiajun, CHEN Yongjun. Simultaneous hepatectomy and splenectomy in treatment of portal hypertension and hypersplenism complicated by primary liver cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 139-144.
| [1] |
Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
doi: 10.3322/caac.21660 URL |
| [2] | 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 中华外科杂志, 2022, 60(4):273-309. |
| [3] |
Xiao H, Zhang B, Mei B, et al. Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation[J]. Medicine (Baltimore), 2015, 94(7):e495.
doi: 10.1097/MD.0000000000000495 URL |
| [4] |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
doi: 10.1016/S0140-6736(18)30010-2 URL |
| [5] |
Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification[J]. Semin Liver Dis, 1999, 19(3):329-338.
doi: 10.1055/s-2007-1007122 pmid: 10518312 |
| [6] |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236.
doi: 10.1016/j.jhep.2018.03.019 URL |
| [7] |
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380.
doi: 10.1002/hep.29086 pmid: 28130846 |
| [8] |
Lake-Bakaar G, Ahmed M, Evenson A, et al. Management of hepatocellular carcinoma in cirrhotic patients with portal hypertension: relevance of Hagen-Poiseuille′s Law[J]. Liver Cancer, 2014, 3(3-4):428-438.
doi: 10.1159/000343871 pmid: 26280004 |
| [9] |
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoem-bolization improves survival[J]. Hepatology, 2003, 37(2): 429-442.
doi: 10.1053/jhep.2003.50047 pmid: 12540794 |
| [10] |
Bai XM, Cui M, Yang W, et al. The 10-year survival analysis of radiofrequency ablation for solitary hepatocellular carcinoma 5 cm or smaller: primary versus recurrent HCC[J]. Radiology, 2021, 300(2):458-469.
doi: 10.1148/radiol.2021200153 URL |
| [11] |
Kim NH, Lee T, Cho YK, et al. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization[J]. J Gastroenterol Hepatol, 2018, 33(7):1397-1406.
doi: 10.1111/jgh.14083 URL |
| [12] |
Choi JW, Chung JW, Lee DH, et al. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Eur Radiol, 2018, 28(5):2184-2193.
doi: 10.1007/s00330-017-5145-9 pmid: 29218611 |
| [13] |
Scheiner B, Ulbrich G, Mandorfer M, et al. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma[J]. United European Gastroenterol J, 2019, 7(6):850-858.
doi: 10.1177/2050640619840199 URL |
| [14] |
Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260(2):329-340.
doi: 10.1097/SLA.0000000000000236 URL |
| [15] |
Liu H, Wang ZG, Fu SY, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan Criteria[J]. Br J Surg, 2016, 103(4):348-356.
doi: 10.1002/bjs.10061 pmid: 26780107 |
| [16] |
Oh JH, Sinn DH, Choi GS, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan Criteria[J]. Ann Surg Treat Res, 2020, 99(4):238-246.
doi: 10.4174/astr.2020.99.4.238 URL |
| [17] |
Harada N, Shirabe K, Maeda T, et al. Comparison of the outcomes of patients with hepatocellular carcinoma and portal hypertension after liver resection versus radiofrequency ablation[J]. World J Surg, 2016, 40(7):1709-1719.
doi: 10.1007/s00268-016-3465-6 URL |
| [18] |
Qiu J, Zheng Y, Shen J, et al. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: a propensity score mat-ching study[J]. Surgery, 2015, 158(5):1235-1243.
doi: 10.1016/j.surg.2015.04.002 URL |
| [19] | 陈孝平, 吴在德, 裘法祖. 肝癌切除联合脾切除治疗肝癌合并肝硬化、脾功能亢进[J]. 中华外科杂志, 2005, 43(7):442-446. |
| [20] |
Nagasue N, Kohno H, Tachibana M, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis[J]. Ann Surg, 1999, 229(1):84-90.
pmid: 9923804 |
| [21] |
Oh JW, Ahn SM, Kim KS, et al. The role of splenectomy in patients with hepatocellular carcinoma and secondary hypersplenism[J]. Yonsei Med J, 2003, 44(6):1053-1058.
doi: 10.3349/ymj.2003.44.6.1053 URL |
| [22] | Li W, Shen SQ, Wu SM, et al. Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis[J]. Onco Targets Ther, 2015, 8:2129-2137. |
| [23] |
Takeishi K, Kawanaka H, Itoh S, et al. Impact of splenic volume and splenectomy on prognosis of hepatocellular carcinoma within Milan Criteria after curative hepatectomy[J]. World J Surg, 2018, 42(4):1120-1128.
doi: 10.1007/s00268-017-4232-z pmid: 28920178 |
| [24] |
Kong J, Shen S, Wang W. Synchronous hepatectomy and splenectomy vs. hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension: a systematic review and meta-analysis[J]. J Surg Oncol, 2019, 119(7):964-973.
doi: 10.1002/jso.25392 URL |
| [25] |
Chen ZL, Yao LQ, Pu JL, et al. Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: a multicenter propensity score matching analysis[J]. Eur J Surg Oncol, 2022, 48(5):1078-1086.
doi: 10.1016/j.ejso.2021.11.118 URL |
| [26] | Jiang W, Li Y, Wei W, et al. Spleen contributes to restraint stress induced hepatocellular carcinoma progression[J]. Int Immunopharmacol, 2020, 83:106420. |
| [27] |
Li L, Duan M, Chen W, et al. The spleen in liver cirrhosis: revisiting an old enemy with novel targets[J]. J Transl Med, 2017, 15(1):111.
doi: 10.1186/s12967-017-1214-8 URL |
| [28] |
Akahoshi T, Hashizume M, Tanoue K, et al. Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor β-1[J]. J Gastroenterol Hepatol, 2002, 17(1):59-65.
doi: 10.1046/j.1440-1746.2002.02667.x URL |
| [29] | Xie XL, Liu X, Ou J. Is synchronous hepatectomy and splenectomy superior to hepatectomy alone for selected patients with hepatocellular carcinoma and clinically significant portal hypertension?[J]. J Surg Oncol, 2019, 120(2):316-317. |
| [30] |
Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther, 2010, 31(3):366-374.
doi: 10.1111/j.1365-2036.2009.04182.x URL |
| [31] | 孙勇伟, 罗蒙, 陈炜, 等. 门静脉高压症外科手术后门静脉系统血栓形成[J]. 外科理论与实践, 2006, 11(3):198-200. |
| [32] |
Wu Y, Li H, Zhang T, et al. Splanchnic vein thrombosis in liver cirrhosis after splenectomy or splenic artery embolization: a systematic review and meta-analysis[J]. Adv Ther, 2021, 38(4):1904-1930.
doi: 10.1007/s12325-021-01652-7 URL |
| [33] |
Rottenstreich A, Kleinstern G, Spectre G, et al. Thromboembolic events following splenectomy: risk factors, prevention, management and outcomes[J]. World J Surg, 2018, 42(3):675-681.
doi: 10.1007/s00268-017-4185-2 pmid: 28808782 |
| [34] | Xu L, Qi X, Li H, et al. Prevalence of portal or splenic vein thrombosis in cirrhotic patients after splenectomy: a systematic review and meta-analysis of observational studies[J]. Int J Clin Exp Med, 2016, 9(4):7534-7547. |
| [35] | 张裕, 刘福全. 门静脉系统血栓的抗凝药物选择[J]. 临床肝胆病杂志, 2018, 34(10):2047-2052. |
| [36] | 陈敬宇, 江艺, 张小进. 术前脾切除对肝移植治疗门脉高压症的影响[J]. 中华肝胆外科杂志, 2014, 20(8):572-576. |
| [37] | 许世磊, 刘剑戎, 张英才, 等. 术前脾切除对肝移植术后预后的影响[J]. 中华消化外科杂志, 2018, 17(10):1008-1012 |
| [38] |
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, sta-ging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2):723-750.
doi: 10.1002/hep.29913 pmid: 29624699 |
| [39] | Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific cli-nical practice guidelines on the management of hepatocel-lular carcinoma: a 2017 update[J]. Hepatol Int,2017, 11(4):317-370. |
| [40] | 中华医学会外科学分会脾及门静脉高压外科学组. 门静脉高压合并肝癌的临床诊疗专家共识(2022版)[J]. 中华外科杂志, 2022, 60(4):310-320. |
| [41] |
Giannini EG, Savarino V, Farinati F, et al. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients[J]. Liver Int, 2013, 33(10):1594-1600.
doi: 10.1111/liv.12199 pmid: 23654354 |
| [42] |
Midorikawa Y, Takayama T, Higaki T, et al. Selection of patients with esophageal varices for liver resection of hepatocellular carcinoma[J]. Biosci Trends, 2021, 14(6):436-442.
doi: 10.5582/bst.2020.03329 pmid: 33055464 |
| [43] | Liu X, Chen Z, Yu M, et al. Safety of simultaneous hepatectomy and splenectomy in the treatment of hepatocellular carcinoma complicated with hypersplenism: a meta-analysis[J]. Gastroenterol Res Pract, 2019, 2019:9065845. |
| [44] | Zhong JH, Li H, Xiao N, et al. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension[J]. PLoS One, 2014, 9(9):e108755. |
| [45] | 中华医学会外科学分会肝脏外科学组. 肝细胞癌外科治疗方法的选择专家共识(2016年第3次修订)[J]. 中华消化外科杂志, 2017, 16(2):113-115. |
| [46] |
Chen XP, Wu ZD, Huang ZY, et al. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism[J]. Br J Surg, 2005, 92(3):334-339.
doi: 10.1002/bjs.4776 URL |
| [47] |
Wu CC, Cheng SB, Ho WM, et al. Appraisal of concomitant splenectomy in liver resection for hepatocellular carcinoma in cirrhotic patients with hypersplenic thrombocytopenia[J]. Surgery, 2004, 136(3):660-668.
doi: 10.1016/j.surg.2004.01.010 URL |
| [48] |
Sugimachi K, Ikeda Y, Tomikawa M, et al. Appraisal of hepatic resection in the treatment of hepatocellular carcinoma with severe thrombocytopenia[J]. World J Surg, 2008, 32(6):1077-1081.
doi: 10.1007/s00268-007-9442-3 pmid: 18338210 |
| [1] | YE Feng, GONG Xiaoyong, REN Jiajun, CAI Qiang, CHEN Sheng. Application of ERCP in diagnosis and treatment of biliary complications during perioperative period of primary liver cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 355-360. |
| [2] | CHANG Jessica, CHEN Xuxiao, CHEN Yongjun. Role of the spleen in patients with liver cancer and cirrhosis [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 394-398. |
| [3] | ZHANG Hui, GONG Ling, GUO Qian, LUO Yan. Retrospective study on sugammadex for reversal of neuromuscular blockade after radiofrequency ablation of hepatic carcinoma under general anesthesia [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 72-76. |
| [4] | ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing. Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482. |
| [5] | YIN Yanjiang, LUO Zhiwen, CHEN Xiao, ZHANG Yefan, HUANG Zhen, ZHAO Hong, ZHAO Jianjun, LI Zhiyu, ZHOU Jianguo, CAI Jianqiang, BI Xinyu. Relationship between surgical margin and prognosis of patients with intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 221-228. |
| [6] | CHEN Congyan, WANG Junqing, CHEN Yongjun. Gut microbiota and mechanism of liver cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 256-260. |
| [7] | SUN Huichuan. Current status and perspectives of conversion therapy for hepatocellular carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 134-138. |
| [8] | MA Jingqin, YANG Minjie, YAN Zhiping. Precision transarterial chemoembolization: treatment goal and embolic endpoint [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133. |
| [9] | BAO Quan, XING Baocai. Surgical treatment strategy for complex bilateral multiple liver metastases of colorectal carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130. |
| [10] | CAO Jun, CHEN Yajin. Laparoscopic anatomic hepatectomy in treatment of hepatocellular carcinoma: standardization and think deeply [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 123-127. |
| [11] | FENG Hao, LÜ Zicheng, XIA Qiang. Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122. |
| [12] | HUANG Jiwei, QIU Guoteng, ZENG Yong. Advances in surgical treatment of hepatocellular carcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118. |
| [13] | FANG Cheng, XIA Yong, WANG Kui, SHEN Feng. Conversion therapy for intrahepatic cholangiocarcinoma: status and perspectives [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 107-112. |
| [14] | LIU Shenyang, TANG Zhaohui, QUAN Zhiwei. Advances in surgical treatment of intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 100-106. |
| [15] | . [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 93-94. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
